Page 22 - MemoriaSAM-Eng

SCIENTIFIC PROGRAMMES

Depression

Programme The mission of the CIBERSAM Depression Programme is to carry out collaborative pro-
jects between basic and clinical investigators: ranging from animal models to patients,
Description
genetics to clinical, including neurochemistry and molecular biology. For that purpose,

the programme includes clinical and basic groups with extensive experience in trans-
lational research.

The research projects focus on 3 main focal points: Epidemiology and prevention of

depression; neurobiological basis of mood disorders; efficacy, resistance and new ther-
apeutic targets in depression.

The main lines of research are:

• Mechanism of action of antidepressants through the study of different receptors.

• Cellular and molecular basis of depression and of the mechanism of action of antide-

pressant drugs. Intracellular signaling targets. Phenotype and molecular characteriza-

tion.

• Gene-environment interaction in depression. Genetic predisposition and drug response
factors.

• New therapeutic targets. Neuroplasticity and serotonergic neurotransmission. Endo-

cannabinoid system and antidepressant responses.

• New therapeutic tools in depression: Interfering RNA (siRNA), ketamine.

• Deep brain stimulation in depression. Clinical trials in patients. DBS in animal models.

• Validation of various evaluation instruments and change in depressive patients.

• First depressive episodes and neurotoxicity.

• MR study on the different stages of major depression.

• Origin and consequences of neuroinflammation in depression.
13
• Treatment with TEC: links to neuropsychological and quality of life impairments.
0
2
RT
• Incidence of depression in patients with dementia.
O
EP
• Analysis of suicidal behavior and development of prevention programmes. Suicide in- R
cidence, related factors and use of antidepressants in the child-adolescent population.
AL
U
• Psychosocial difficulties and occupational disability in patients with depression.
NN
A
• Socio-demographic, clinical and/or pharmacological factors involved in the response to /
M
different therapeutic strategies.
SA
R
BE
CI

22